Skip to content
Search

Latest Stories

PB Conference: 'Community pharmacy integration is vital for GPs to ensure continuous service to patients'

Integration of community pharmacy into local health system and primary care network is vital to alleviate workload pressure on general practice and provide an uninterrupted service to patients, said Newham GP Farzana Hussain.

Looking at the appointments this year, there is a 30 per cent rise in demand from patients, and GPs are struggling to match up, she added.


In this scenario, “I think that our community pharmacists are such an asset to us,” to meet that growing demand, said Hussain, who is clinical director of Newham Central 1 Primary Care Network and a senior partner at the Project Surgery in Plaistow.

Citing her experience of collaboration with the neighboring Rohpharm pharmacy, she said, “We are a natural pairing.”

“We are sending just in our practice alone 5,000 patients, about eight CPCS referrals a day. If I put that in context for you, that's half a clinic a day per GP, (with) that we are able to give extra appointments,” she said.

Rohpharm director Jignesh Patel also acknowledged the significance of integration saying, “it is the first time I think in history of pharmacy that pharmacists and GPs and primary care are actually starting to work together.”

Further to back his point, Patel quoted last year’s instance when during the flu season Hussain’s practice did not get flu vaccines, and Rohpharm provided the shots to ensure patients got their jabs in time and there was no disruption to the service.

Similarly, Hussain was quick to return the favour when Rohpharm’s vaccine stock exhausted.

“So that cool coordination and working together meant that our patients didn't actually suffer,” Patel said.

After being elected as the co-chair of the Newham GP and Community Pharmacy Forum, Patel is trying to get all pharmacists to work together and put a system in place.

Likewise, to strengthen the integration model and to boost confidence amongst the GPs about the pharmacists’ skills, Hussain ran a pilot at The Project Surgery, referring at least one appointment to the community pharmacist.

She added: “We know that we have that failsafe mechanism that if somebody can't be dealt with by community pharmacists, they will be referred back to the practice and they will be seen within 24 hours. So that gave our practices a lot of confidence that the system works (for them).”

“I think I would be bold to say that I feel the clinical pharmacist is a great addition to a PCN.

“And I would like to see a day in the not too distant future where our community pharmacists are actually sitting on the PCN board. I know that isn't legislated at the moment, and I think it should be.”

Dr Hussain and Patel were interviewed by chair of Pharmacy Business Conference Michael Holden. The three-way interview ran in the first session of the 6th annual Pharmacy Business Conference on Tuesday, September 21.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less